Research Paper Volume 16, Issue 2 pp 1218—1236
Development and validation of a combined cuproptosis and immunogenic cell death prognostic model for diffuse large B-cell lymphoma
Figure 3. Validation of the prognostic risk signature. (A, B) Stratification of CRIRLs into risk subgroups in training cohort. (C, D) Stratification of CRIRLs into risk subgroups in validation cohort. (E, F) Analysis of clinical prognosis outcomes for risk subgroups in training cohort and validation set of CRIRLs. (G, H) Expression of the 4 prognostic CRIRLs in training cohort and validation set.